161 related articles for article (PubMed ID: 3034850)
1. Clinical efficacy and safety of sulbactam/ampicillin in patients suffering from chronic liver disease.
Galante D; Esposito S; Barba D; Ruffilli MP
J Antimicrob Chemother; 1987 Apr; 19(4):527-32. PubMed ID: 3034850
[TBL] [Abstract][Full Text] [Related]
2. Sulbactam plus ampicillin: interim review of efficacy and safety for therapeutic and prophylactic use.
Lees L; Milson JA; Knirsch AK; Greenhalgh K
Rev Infect Dis; 1986; 8 Suppl 5():S644-50. PubMed ID: 3026019
[TBL] [Abstract][Full Text] [Related]
3. Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.
Campoli-Richards DM; Brogden RN
Drugs; 1987 Jun; 33(6):577-609. PubMed ID: 3038500
[TBL] [Abstract][Full Text] [Related]
4. Ampicillin/sulbactam (Unasyn).
Med Lett Drugs Ther; 1987 Aug; 29(747):79-81. PubMed ID: 3039328
[No Abstract] [Full Text] [Related]
5. Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections.
Akova M; Ozcebe O; Güllü I; Unal S; Gür D; Akalin S; Tokgözoglu M; Telatar F; Akalin HE
J Chemother; 1996 Aug; 8(4):284-9. PubMed ID: 8873834
[TBL] [Abstract][Full Text] [Related]
6. A non-comparative study of parenteral ampicillin and sulbactam in intra-thoracic and intra-abdominal infections.
Mehtar S; Croft RJ; Hilas A
J Antimicrob Chemother; 1986 Mar; 17(3):389-96. PubMed ID: 3009384
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of aminopenicillins combined with sulbactam, clavulanic acid, or amdinocillin against bacteria isolated from patients with complicated urinary tract infections.
Naber KG; Wittenberger R
Rev Infect Dis; 1986; 8 Suppl 5():S604-8. PubMed ID: 3026011
[TBL] [Abstract][Full Text] [Related]
8. Ampicillin/sulbactam: current status in severe bacterial infections.
Rafailidis PI; Ioannidou EN; Falagas ME
Drugs; 2007; 67(13):1829-49. PubMed ID: 17722953
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind comparison of sulbactam/ampicillin and clindamycin for the treatment of aerobic and aerobic-anaerobic infections.
Reinhardt JF; Johnston L; Ruane P; Johnson CC; Ingram-drake L; MacDonald K; Ward KW; Mathisen G; George WL; Finegold SM
Rev Infect Dis; 1986; 8 Suppl 5():S569-75. PubMed ID: 3026005
[TBL] [Abstract][Full Text] [Related]
10. Sulbactam/ampicillin for treatment of polymicrobial pelvic infections.
Hemsell DL
Drugs; 1986; 31 Suppl 2():22-5. PubMed ID: 3013569
[TBL] [Abstract][Full Text] [Related]
11. Clinical, bacteriological and pharmacokinetic results from an open trial of sultamicillin in patients with acute exacerbations of chronic bronchitis.
Davies BI; Maesen FP; van Noord JA
J Antimicrob Chemother; 1984 Feb; 13(2):161-70. PubMed ID: 6323377
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of sulbactam/ampicillin in pediatric infections caused by ampicillin-resistant or penicillin-resistant organisms.
Syriopoulou V; Bitsi M; Theodoridis C; Saroglou I; Krikos X; Tzanetou K
Rev Infect Dis; 1986; 8 Suppl 5():S630-3. PubMed ID: 3026016
[TBL] [Abstract][Full Text] [Related]
13. Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection.
Retsema JA; English AR; Girard A; Lynch JE; Anderson M; Brennan L; Cimochowski C; Faiella J; Norcia W; Sawyer P
Rev Infect Dis; 1986; 8 Suppl 5():S528-34. PubMed ID: 3026001
[TBL] [Abstract][Full Text] [Related]
14. A comparison of parenteral sulbactam/ampicillin versus clindamycin/gentamicin in the treatment of pelvic inflammatory disease.
Gunning J
Drugs; 1986; 31 Suppl 2():14-7. PubMed ID: 3013567
[TBL] [Abstract][Full Text] [Related]
15. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
16. Treatment of infections caused by ampicillin-resistant pathogens with a combination of ampicillin and CP-45,899.
Plouffe JF
Antimicrob Agents Chemother; 1982 Mar; 21(3):519-20. PubMed ID: 6285812
[TBL] [Abstract][Full Text] [Related]
17. In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.
Wexler HM; Harris B; Carter WT; Finegold SM
Antimicrob Agents Chemother; 1985 May; 27(5):876-8. PubMed ID: 2990330
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of sulbactam/ampicillin in Japan.
Shimada K
Diagn Microbiol Infect Dis; 1989; 12(4 Suppl):171S-174S. PubMed ID: 2686916
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sequential treatment with parenteral sulbactam/ampicillin and oral sultamicillin for skeletal infections in children.
Aronoff SC; Scoles PV; Makley JT; Jacobs MR; Blumer JL; Kalamchi A
Rev Infect Dis; 1986; 8 Suppl 5():S639-43. PubMed ID: 3026018
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with intramuscular sulbactam/ampicillin in the outpatient treatment of various infections. A multicentre trial.
Güneren MF
Drugs; 1988; 35 Suppl 7():57-68. PubMed ID: 3065055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
